Archive: 17/04/2018

Study shows potential cost savings for early detection and treatment of type 2 diabetes

Health checks, including diabetes risk assessment, have been introduced in a number of countries. However, there are few population-based trials assessing the benefits, harms and costs of these screening programmes, and these ...

Apr 17, 2018

Hope for new treatment of severe epilepsy

Researchers at Lund University in Sweden believe they have found a method that in the future could help people suffering from epilepsy so severe that all current treatment is ineffective. "In mice studies, we succeeded in ...

Apr 17, 2018

Protective effect of CD9 and CD81 in COPD and accelerated aging

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that causes obstructed airflow, and it is expected to be the third leading cause of death globally by 2030. At present, only symptomatic therapies for ...

Apr 17, 2018

0

8

Researchers succeed in cultivating cartilage from stem cells

Researchers have produced stable joint cartilage from adult stem cells originating from bone marrow. This was made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers ...

Apr 17, 2018

0

1215

New disease model to facilitate development of ALS and MS therapies

Researchers at Karolinska Institutet in Sweden have developed a new disease model for neurodegenerative diseases such as ALS and MS that can be used to develop new immunotherapies. The model is described in a publication ...

Apr 17, 2018

0

107

Innate immune adaptor TRIF confers neuroprotection in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease damaging motor neurons in brain and spinal cords. ALS patients show progressive muscle weakness and atrophy, leading to a fatal respiratory muscle paralysis. ...

Apr 17, 2018

0

3

US firm Advent to buy Sanofi's generics unit

US private equity firm Advent International has agreed to acquire Zentiva, French pharmaceutical giant Sanofi's European generics arm, for 1.9 billion euros ($2.4 billion), a statement said Tuesday.

Apr 17, 2018

0

4

Novartis to inject $100 mn into malaria drug research

Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 ...

Apr 17, 2018